SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: June 16, 1997 - Commission File No. 0-17746
------------- -------
SAFE AID PRODUCTS INCORPORATED
_____________________________________________________________
(Exact name of Registrant as specified in its Charter)
Delaware 22-2824492
- ------------------------------- -------------------------------
(State or other jurisdiction of (IRS Employer ID No.)
incorporation or organization)
c/o Lazer, Aptheker, Feldman,
Rosella & Yedid, LLP
225 Old Country Road
Melville, New York 11747
- ------------------------------- -------------------------------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, (516) 364-3887
including area code: -------------------------------
<PAGE>
STATUS OF JOINT VENTURE
-----------------------
Item 5. Other Events
- ---------------------
In connection with the joint venture between CC Plus and the Company for the
development of nasally administered aspirin, the Company has received
communication from CC Plus indicating that CC Plus does not believe it is
required to expend $500,000 towards the development and marketing of the Product
and further indicating its intent not to pursue the matter any further. The
Company disputes the position of CC Plus and is exploring its options. No
further action will be taken on the development of the Product through the
joint venture until these issues are resolved.
<PAGE>
Signatures
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SAFE AID PRODUCTS INCORPORATED
By: s/Stanley Snyder
-------------------------
Stanley Snyder, President
"Dated: June 16, 1997"
